Elidentus, MB - financials and debts

Company age: 3 y. 8 mo.

Update

Elidentus - Company finances

EUR
2023
From: 2023-01-11
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 57,955 76,080 96,750
Profit before tax 40,954 33,960 63,065
Net profit 40,954 32,262 59,281
Equity 41,054 73,316 132,597
Liabilities 1,644 11,854 11,187
Non-current assets 1,404 1,053 702
Current assets 41,294 84,117 143,082
Total assets 42,698 85,170 143,784
Taxes paid
STI taxes 136 16 1,698
Financial indicators
Revenue change y/y - +31.3% +27.2%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 95.9% 37.9% 41.2%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 99.8% 44.0% 44.7%
Profit margin Net profit margin. Shows the overall profitability of the company. 70.7% 42.4% 61.3%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 70.7% 44.6% 65.2%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.0 0.2 0.1
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 57,955 - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Elidentus - Social security debts

From To Debt, €
2024-04-03 2024-04-30 193.50
2024-03-01 2024-04-02 129.00
2024-02-01 2024-02-29 64.50
2023-10-03 2023-10-31 58.63
2023-08-17 2023-09-30 1.94

Elidentus - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Elidentus, MB (company code 306217661) is a small partnership operating in diagnostic imaging services and medical laboratory activities. In 2025, the latest financial year, the company generated revenue of €96.8K, up 27.2% year on year and 66.9% over two years. Net profit reached €59.3K, compared with €32.3K in 2024 and €41.0K in 2023, showing a clear improvement in profitability after a lower result in 2024. The 2025 net profit margin was 61.3%, indicating that the business converted a large share of turnover into earnings.

The balance sheet strengthened materially during the period. Total assets increased from €42.7K in 2023 to €85.2K in 2024 and €143.8K in 2025. Equity rose to €132.6K, while liabilities remained limited at €11.2K, resulting in an equity ratio of 92.2% and debt-to-equity of 0.08. Asset turnover stood at 0.67x in 2025. Return on equity was 44.7% and return on assets 41.2%, reflecting strong profitability relative to the company’s asset base.